Hormonal
Higher Chinese visceral adiposity index (CVAI) is significantly associated with increased prevalence of cardiovascular disease (CVD) and diabetic kidney disease (DKD) in diabetic adults, independent of BMI.
For diabetic patients, tracking visceral fat risk via the Chinese Visceral Adiposity Index (CVAI) provides a more accurate prediction of heart and kidney disease risk than BMI alone. Clinicians should prioritize CVAI calculations to identify high-risk individuals for early intervention, particularly women who show a stronger association between CVAI and kidney disease.
In men, a one standard deviation (SD) increase in CVAI level was significantly associated with a greater prevalence of CVD (OR 1.35; 95% CI 1.13, 1.62) and DKD (OR 1.38; 95% CI 1.12, 1.70)... In women, a one SD increase in CVAI level was significantly associated with a greater prevalence of CVD (OR 1.32; 95% CI 1.04, 1.69) and DKD (OR 2.50; 95% CI 1.81, 3.47)... CVAI was most strongly associated with the prevalence of CVD and DKD among the abdominal obesity indices
Why this rating
Large community-based cross-sectional study (n=4658) with robust adjustment for confounders.
Source
Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference
Heng Wan et al. · Cardiovascular Diabetology · 2020
DOI 10.1186/s12933-020-01095-4
More from this paper
- Neck circumference (NC) is uniquely associated with the prevalence of common carotid artery (CCA) plaque in diabetic adults, independent of other abdominal obesity indices.Good
- Abdominal obesity indices (CVAI, NC, WC, WHR, LAP, VAI) are not associated with the prevalence of diabetic retinopathy (DR) in diabetic adults, regardless of BMI adjustment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →